Randolph Lopez

Company: A-Alpha Bio Inc.

Job title: Co-founder & Chief Technology Officer

Seminars:

Machine Learning for Rapid Screening of Weak Degrons Across Multiple E3 Ligases 9:30 am

Pinpointing how identification of latent (i.e., real but sub-physiological) E3 ligase-target interactions is a major bottleneck in the clinical advancement of molecular glues Utilizing high-throughput generation of ligase-peptide binding data and machine learning, we can construct in silico binding models that predict latent interactions and stabilizing mutations Using these models, we can dramatically improve the…Read more

day: Day Two